Quality of life · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Adults with lateral elbow pain
1 finding from 1 review
Adverse events · Adults with lateral elbow pain
Topical NSAIDs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of dementia · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · older people with age‐related memory loss
NSAIDs (celecoxib) may leads to higher adverse events – gastrointestinal compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive decline · older people with age‐related memory loss
1 finding from 1 review
Activities of daily living · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
850 participants
High
Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in withdrawals due to adverse events Due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.75 [0.46, 1.21]
1165 participants
High
BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
190 participants
Moderate
BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
356 participants
High
BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiographic progression · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Function: mean change in pain with movement from baseline on4‐point (0 to 3, 0 best function) Likert scale · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Global assessment of treatment success · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Health‐related quality of life (mental) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 2.34 [1.33, 4.14]
Studies not reported
Moderate